Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)

Published:2023-11-18 Issue:1 Volume:130 Page:53-62
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Zhao Jimmy L.,Antonarakis Emmanuel S.,Cheng Heather H.,George Daniel J.^ORCID,Aggarwal Rahul^ORCID,Riedel Elyn,Sumiyoshi Takayuki,Schonhoft Joseph D.,Anderson Amanda,Mao Ninghui,Haywood Samuel,Decker Brooke,Curley Tracy,Abida Wassim,Feng Felix Y.,Knudsen Karen,Carver Brett,Lacouture Mario E.,Wyatt Alexander W.^ORCID,Rathkopf Dana^ORCID

Funder

Celgene

Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada

Gateway for Cancer Research

JLZ was supported by a K12 Paul Calabresi Career Development Award for Clinical Oncology and a Prostate Cancer Foundation Young Investigator Award.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-023-02487-5.pdf

Reference44 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

2. American Cancer Society. Cancer Statistics Center. 2022. http://cancerstatisticscenter.cancer.org.

3. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. https://doi.org/10.1056/NEJMoa1405095.

4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. https://doi.org/10.1056/NEJMoa1014618.

5. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701–11. https://doi.org/10.1038/nrc4016.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and therapeutic potential of DNA-dependent protein kinase inhibitors;Bioorganic Chemistry;2024-09

2. Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators;Cell Death & Disease;2024-08-03

3. New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2024-06

4. Exploiting the DNA Damage Response for Prostate Cancer Therapy;Cancers;2023-12-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3